Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients

Cancer‐associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer‐induced cachexia in patients with earlier stages of disease.

[1]  T. Pawlik,et al.  Predictors of Pancreatic Cancer–Associated Weight Loss and Nutritional Interventions , 2017, Pancreas.

[2]  A. Fiorillo,et al.  Effects of acute physical exercise on oxidative stress and inflammatory status in young, sedentary obese subjects , 2017, PloS one.

[3]  B. Adams-Huet,et al.  The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome. , 2017, Journal of diabetes and its complications.

[4]  G. Marko‐Varga,et al.  Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma , 2017, The British journal of surgery.

[5]  M. Muscaritoli,et al.  Perspectives of health care professionals on cancer cachexia: results from three global surveys , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Anker,et al.  Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016 , 2016, Journal of cachexia, sarcopenia and muscle.

[7]  Richard Nicoletti,et al.  Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss. , 2016, Oncology letters.

[8]  T. Welling,et al.  GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. , 2016, Cancer discovery.

[9]  R. Parish,et al.  Resting Heart Rate Variability, Inflammation, and Insulin Resistance in Overweight and Obese Adolescents. , 2016, Metabolic syndrome and related disorders.

[10]  J. Davis,et al.  Role of MCP-1 on Inflammatory Processes and Metabolic Dysfunction Following High-Fat Feedings in the FVB/N Strain , 2015, International Journal of Obesity.

[11]  A. Vigano,et al.  MAP3K11/GDF15 axis is a critical driver of cancer cachexia , 2015, Journal of cachexia, sarcopenia and muscle.

[12]  J. Otoch,et al.  Cachexia‐associated adipose tissue morphological rearrangement in gastrointestinal cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.

[13]  G. Lesinski,et al.  Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer , 2015, Clinical Cancer Research.

[14]  G. Trinchieri,et al.  Systemic Inflammation in Cachexia – Is Tumor Cytokine Expression Profile the Culprit? , 2015, Front. Immunol..

[15]  S. Anker,et al.  Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015 , 2015, Journal of cachexia, sarcopenia and muscle.

[16]  Shiying Yu,et al.  An Epidemiological Survey of Cachexia in Advanced Cancer Patients and Analysis on Its Diagnostic and Treatment Status , 2015, Nutrition and cancer.

[17]  Shi Qian,et al.  How to analyze tumor stage data in clinical research. , 2015, Journal of thoracic disease.

[18]  Richard Nicoletti,et al.  Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.

[19]  T. Mukohara,et al.  Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer , 2014, PloS one.

[20]  N. Wentzensen,et al.  Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[21]  C. Jenkinson,et al.  The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus , 2014, Acta Diabetologica.

[22]  R. Browne,et al.  Performance of Multiplex Cytokine Assays in Serum and Saliva among Community-Dwelling Postmenopausal Women , 2013, PloS one.

[23]  Thomas Pausch,et al.  Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. , 2012, Surgery.

[24]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[25]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[26]  Sunita Ghosh,et al.  Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma , 2012, British Journal of Cancer.

[27]  A. Sümer,et al.  The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic , 2012, Human & experimental toxicology.

[28]  Dale P Sandler,et al.  Accuracy and reliability of self-reported weight and height in the Sister Study , 2011, Public Health Nutrition.

[29]  M. Ashraf,et al.  Artemisinins and immune system. , 2011, European journal of pharmacology.

[30]  T. Hyslop,et al.  Serum Monocyte Chemoattractant Protein-1 in Pancreatic Cancer , 2011, Journal of oncology.

[31]  F. López‐Soriano,et al.  Anti-inflammatory therapies in cancer cachexia. , 2011, European journal of pharmacology.

[32]  J. Margolick,et al.  Multisite Comparison of High-Sensitivity Multiplex Cytokine Assays , 2011, Clinical and Vaccine Immunology.

[33]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[34]  P. Iversen,et al.  Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer , 2011, Archives of physiology and biochemistry.

[35]  M. Krzystek-Korpacka,et al.  Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract. , 2010, Cytokine.

[36]  L. Kuller,et al.  Circulating levels of 8 cytokines and marine n-3 fatty acids and indices of obesity in Japanese, white, and Japanese American middle-aged men. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[37]  G. Taffet,et al.  Adipokines in Patients With Cancer Anorexia and Cachexia , 2010, Journal of Investigative Medicine.

[38]  M. Tisdale Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[39]  G. Wakabayashi,et al.  Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs , 2009, International Journal of Clinical Oncology.

[40]  H. Friess,et al.  Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary function , 2009, BMC Cancer.

[41]  G. Frühbeck,et al.  Circulating Markers of Inflammation and Their Link to Indices of Adiposity , 2008, Obesity Facts.

[42]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[43]  H. Friess,et al.  Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.

[44]  T. McDonald,et al.  Monocyte Chemoattractant Protein-1 Deficiency Fails to Restrain Macrophage Infiltration Into Adipose Tissue , 2008, Diabetes.

[45]  G. Frühbeck,et al.  Proinflammatory Cytokines in Obesity: Impact of Type 2 Diabetes Mellitus and Gastric Bypass , 2007, Obesity surgery.

[46]  Graham M Lord,et al.  Absence of CC Chemokine Ligand 2 Does Not Limit Obesity-Associated Infiltration of Macrophages Into Adipose Tissue , 2007, Diabetes.

[47]  C. Ko,et al.  Validation of the 6th edition AJCC pancreatic cancer staging system , 2007, Cancer.

[48]  J. Fernández-Real,et al.  Monocyte Chemoattractant Protein‐1 in Obesity and Type 2 Diabetes. Insulin Sensitivity Study , 2007, Obesity.

[49]  T. Kadowaki,et al.  Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance* , 2006, Journal of Biological Chemistry.

[50]  R. Kitazawa,et al.  MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.

[51]  R. Yu,et al.  Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters , 2006, International Journal of Obesity.

[52]  R. Skipworth,et al.  Cancer cachexia and fatigue. , 2006, Clinical medicine.

[53]  H. Kotani,et al.  Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice* , 2003, Journal of Biological Chemistry.

[54]  P. Allavena,et al.  The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. , 2003, Cancer research.

[55]  E. Villanueva The validity of self-reported weight in US adults: a population based cross-sectional study , 2001, BMC public health.

[56]  G A Colditz,et al.  Physical activity, obesity, height, and the risk of pancreatic cancer. , 2001, JAMA.

[57]  M. Breslow,et al.  Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[58]  M. Goldberg,et al.  Validity of self-reported weight and height in the French GAZEL cohort , 2000, International Journal of Obesity.

[59]  B. Rollins,et al.  Monocyte chemoattractant protein-1. , 1999, Chemical immunology.

[60]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[61]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.